SCHEMBL24975909

SCHEMBL24975909

CC(C)Oc1ccn2c(I)cnc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.35
BRD4 O60885 1/20 0.33
BRPF1 P55201 1/20 0.33
ALDH1A1 P00352 3/20 0.33
FLT3 P36888 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 2/20 0.33
CYP1A2 P05177 1/20 0.33
MAP4K4 O95819 1/20 0.33
PKM P14618 1/20 0.33
GLA P06280 1/20 0.32
HPGD P15428 1/20 0.32
KIT P10721 1/20 0.32
CSF1R P07333 1/20 0.32
FGFR4 P22455 1/20 0.32
DHFR P00374 1/20 0.32
ABL1 P00519 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24976619 0.84 KIT (0.38) ALDH1A1FLT3KDM4EGAAPKM
SCHEMBL16965212 0.84 FLT3 (0.48) FLT3CYP1A2MAP4K4
SCHEMBL24976169 0.83 PRMT5 (0.36) FGFR1BRD4BRPF1ALDH1A1FLT3
SCHEMBL16581904 0.82 FLT3 (0.43) ALDH1A1FLT3KDM4EPKMHPGD
SCHEMBL16582024 0.79 ALDH1A1 (0.38) ALDH1A1FLT3KDM4EGAAGLA
SCHEMBL17437915 0.78 ALDH1A1 (0.43) FGFR1ALDH1A1KDM4EGAAPKM
SCHEMBL24976173 0.76 PDE8A (0.32) FLT3
SCHEMBL27451464 0.76 KDR (0.33) ALDH1A1FLT3KDM4EGAAPKM
SCHEMBL24976623 0.74 NEK2 (0.37) FLT3KITCSF1R
SCHEMBL23104223 0.74 CHRNB2 (0.42) FGFR1CYP1A2KITMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154144-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDRENS HOSPITAL MED CT (US) 2025-05-15 US disclosed
CN-118613480-A Polycyclic IRAK and FLT3 inhibiting compounds and uses thereof 儿童医院医学中心 2024-09-06 CN disclosed
WO-2023009833-A9 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-11-23 WO disclosed
WO-2023009833-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154144-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK3 FGFR1 329/4885BRD4 394/4885BRPF1 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.